Surgical therapy of hepatic fibrolamellar carcinoma;Il carcinoma epatico fibrolamellare. Considerazioni chirurgiche attuali

Annali Italiani di Chirurgia

Volumn 78, Issue 1, 2007, Pages 53-58

  Meriggi, Francesco ^a   Forni, Eugenio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Hepatic fibrolamellar carcinoma; Surgical therapy

Indexed keywords

BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

ADOLESCENT; ARTICLE; BLOOD; CASE REPORT; GYNECOMASTIA; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TUMOR; LYMPHADENECTOMY; MALE; PROGNOSIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; GYNECOMASTIA; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LYMPH NODE EXCISION; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34547433170     PISSN: 0003469X     EISSN: 2239253X     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Farhi DC, Shikes RH, Murari P.J., Silverberg SG: Hepatocellular carcinoma in young people. Cancer, 1983; 52:1516-25.
2. Lack EE, Neave C, Vawter GF: Hepatocellular carcinoma. Review of 32 cases in childhood and adolescence. Cancer, 1983; 52:1510-5.
3. Soreide O, Czerniak A, Bradpiece H., Bloom S, Blumgart L: Characteristics of fibrolamellar hepatocellular carcinoma. A study of nine cases and a review of the literature. Am J Surg, 1986; 151:518-23.
4. Winter SS: Hepatocellular carcinoma. eMedicine.com, Inc., 2005 (http://www.emedicine.com/ped/topic983.htm).
5. Ang PT, Evans H, Pazdur R: Fibrolamellar hepatocellular carcinoma. Therapeutic implications of a ten-year disease-free interval. Am J Clin Oncol, 1991; 14:175-78.
6. Berman HH, Libbey NP, Foster JH: Hepatocellular carcinoma: polygonal cell type with fibrous stroma: an atypical variant with a favourable prognosis. Cancer, 1980; 46:1448-455.
7. Epstein BE, Pajak ThF, Haulk ThL, Herpst JM, Order SE, Abrams RA: Metastatic nonresectable fibrolamellar hepatoma. Prognostic features and natural history. Am J Clin Oncol, 1999; 22:22-28.
8. Friedman AC, Lichtenstein JE, Goodman Z, Fishman E.K., Siegelman SS, Dachman AH: Fibrolamellar hepatocellular carcinoma. Radiology, 1985; 157:583-7.
9. McLarney JK, Rucker PT, Bender G.N., Goodman ZD, Kashitani N, Ros PR: Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. Radiographics, 1999; 19:453-71.
10. Edmondson HA, Steiner PE: Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer, 1954; 7:462-503.
11. Edmondson HA: Differential diagnosis of tumors and tumor-like lesions of the liver in infancy and chilhood. Am J Dis Child, 1956; 91:168-86.
12. Choti M, Sperry JL: Fibrolamellar carcinoma. eMedicine.com, Inc., 2005 (http://www.emedicine.com/med/topic787.htm).
13. Seitz G, Zimmermann A, Friess H., Büchler MW: Adult-type hepatocellular carcinoma in the center of a fibrolamellar hepatocellular carcinoma. Hum Pathol, 2002; 33:765-69.
14. Katzenstein HM, Krailo MD, Malogolowkin M.H., Ortega JA, Qu W, Douglass EC, Feusner J.H., Reynolds M., Quinn JJ, Newman K, Finegold MJ, Haas JE, Sensel MG, Castleberry RP, Bowman LC: Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer, 2003; 97:2006-12.
15. Ringe B, Wittekind C, Weimann A., Tusch G, Pichlmayr R: Results of hepatic resection and transplantation for fibrolamelhir carcinoma. Surg Gynecol Obstet, 1992; 175:299-305.
16. LeBrun DP, Silver MM, Freedman M.H., Phillips MJ: Fibrolamellar carcinoma of the liver in a patient with Fanconi anenua. Hum Pathol, 1991; 22:396-98.
17. Arista-Nasr J., Gutierrez-Villalobos I., Nuncio J., Maldonaldo H, Bornstein-Quevedo L: Fibrolamellar hepatocellular carcinoma in Mexican patients. Pathol Oncol Res, 2002; 8:133-37.
18. Craig JR, Peters RL, Edmondson H.A., Omata M: Fibrolamelbir carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-patho/ogic features. Cancer, 1980; 46:372-79.
19. Yoshimi F, Asato Y, Amemiya R., ltabashi M, Nakamura K: Fibrolamellar hepatocellular carcinoma in a Japanese man: report of a case. Surg Today, 2002; 32:174-9.
20. Davidson BR: Fibrolamellar carcinoma arising in an abnormal liver (letter). J Hepatol, 1990; 11:388.
21. El-Serag H.B., Davila JA: Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology, 2004; 39:798-803.
22. Goodman ZD, Ishak KG, Langloss J.M., Sesterhenn IA, Rabin L: Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer, 1985; 55:124-35.
23. Kaczynski J, Gustavsson B, Hansson G., Wallerstedt S: Fibrolamelbir hepatic carcinoma in an area with a low incidence of primary liver cancer: a retrospective study. Eur J Surg, 1996; 162:367-71.
24. Okada K. Kim YI, Nakashima K, Tada I, Yoshida T, Kobayashi M, Yokoyama S: Fibrolamellar hepatocellular carcinoma coexistent with a hepatocellular carcinoma of common type: Report of a case. Jpn J Surg, 1993; 23:626-31.
25. Okano A, Hajiro K, Takakuwa H., Kobashi Y: Fibrobamellar carcinoma of the liver with a mixture of ordinary hepatocellular carcinoma: a case report. Am J Gastroenterol, 1998; 93:1144-5.
26. Okuda K: Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol, 2002; 17:401-5.
27. Van Eyken P., Sciot R, Brock P., Casteels-Van Daele M, Ramaekers FC, Desmet VJ: Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver. Histopathology, 1990; 17:101-7.
28. Vecchio FM, Fabiano A, Ghirlanda G., Manna R, Massi G: Fibrolamellar carcinoma of the liver: the malignant counterpart of focal nodular hyperplasia with oncocytic change. Am J Clin Pathol, 1984; 81:521-26.
29. Louie-Johnsun M.W., Hewitt PM, Perera D.S., Morris DL: Fibrolamelbir hepatocellular carcinoma in pregnancy. HPB, 2003; 5:191-93.
30. Collier NA, Bloom SR, Hodgson HJF, Weinbren K, Lee Y.C., Blumgart LH: Neurotensin secretion by fibrolamellar carcinoma of the liver. Lancet, 1984; 1:538-40.
31. 12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Br Med J, 1982; 285:840-42.
32. Kew MC, Kirschner MA, Abrahams G.E., Katz M: Mechanism of feminization in primary liver cancer. N Engl J Med, 1977; 296:1084-87.
33. McCloskey JJ, Germain-Lee EL, Perman J.A., Plotnick LP: Gynecomastia as a presenting sign of fibrolamellar carcinoma of the liver. Pediatrics, 1988; 82:379-82.
34. Ichikawa T, Federle MP, Grazioli L, Marsh W: Fibrolamellar hepatocellular carcinoma: pre- and post-therapy evaluation with CT and MR imaging. Radiology, 2000; 217:145-51.
35. Meyer T, Davidson B, Hochhauser D., Dhillon P, Begent R: Fibrolamellar carcinoma: A strategy for management. Proceedings ASCO Annual Meeting, 2001 (Abstract no. 2311).
36. Bedi DG, Kumar R, Morettin L.B., Gourley K: Fibrolamellar carcinoma of the liver: CT, ultrasound and angiography. Case report. Europ J Radiol, 1988; 8:109-12.
37. Suen KC, Magee JF, Halparin L.S., Chan NH, Greene C-A: Fine needle aspiration cytology of fibrolamellar hepatocellular carcinoma. Acta Cytol, 1985; 29:867-72.
38. Teefey SA, Stephens DH, Weiland LH: Calcification in hepatocellular carcinoma: not always an indication of fibrolamellar histology. AJR, 1987; 149:1173-4.'
39. Machado MC, Herman P, Bacchella T., Pugliese V, Pinotti HW: Resection of a fibrolamellar carcinoma of the liver originating in the caudate lobe. Hepato-Gastroenterol, 1995; 42:993-5.
40. Grazi GL, Mazziotti A, Legnani C., Jovine E, Miniero R, Gal-lucci A, Palareti G., Gozzetti G: La des-y-carbossi protrombina nella diagnosi dell'epatocarcinoma. Confronta con gli altri marcatori tumorali Chirurgia, 1994; 7:726-32.
41. Liebman HA, Furie BC, Tong M.J., Blanchard RA, Lo KJ, Lee SD, Coleman M.S., Furie B: Des-y-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med, 1984; 310:1427-431.
42. Nakao A, Virji A, Iwaki Y., Carr B, Iwatsuki S, Starzl E: Abnormal prothrombin (des-y-carboxy prothrombin) in hepatocellular carcinoma. Hepato-Gastroenterol, 1991; 38:450-53.
43. Okuda H, Obata H, Nakanishi T., Furukawa R, Hashimoto E: Production of abnormal prothrombin (des-y-carboxy prothrombin) by hepatocellular carcinoma. An experimental study. J Hepatol, 1987; 4:357-63.
44. Agarwal VR, Takayama K, Van Wyk JJ, Sasano H, Simpson ER, Bulun SE: Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. JCE & M, 1998; 83:1797-1800.
45. Galizia G, Nagasue N, Lieto E., Pignatelli C: Recettori per gli androgeni e gli estrogeni nell'epatocarcinoma. Valutazione epidemiolo-gica, clinica e prognostica. Chirurgia, 1994; 7:583-91.
46. Nagasue N, Galizia G, Yukaya H., Kohno Fl, Chang YC, Ha-yashi T, Nakamura T: Better survival in women than in men after radical resection of hepatocellular carcinoma. Hepato-Gastroenterol, 1989; 36:379-83.
47. Nagasue N, Yu L, Yukaya H., Kohno H, Nakamura T: Androgen and oestrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: impact on intrahepatic recurrence after hepatic resection. Br J Surg, 1995; 82:542-47.
48. Villa E, Dugani A, Fantoni E., Camellini L, Buttafoco P, Grottola A., Pompei G, De Santis M, Ferrari A, Manenti F: Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res, 1996; 56:3883-885.
49. Starzl TE, Iwatsuki S, Shaw BW Jr, Nalesnik MA, Farhi DC, Thiel DHV: Treatment of fibrolamellar hepatoma with partial or total hepatectomy and transplantation of the liver. Surg Gynecol Obstet, 1986; 162:145-48.
50. Yamamoto H, Watanabe K, Takayama W., Yamada S, Fujita Y, Flonda I., Watanabe S, Matsuzaki O, Ryu M: Surgical management for lymph node recurrence of resected fibrolamellar carcinoma of the liver: a case report. Jpn J Clin Oncol, 1995; 25:282-85.